Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011:2011:830260.
doi: 10.1155/2011/830260. Epub 2011 May 18.

Autophagic and apoptotic effects of HDAC inhibitors on cancer cells

Hidemi Rikiishi  1
Affiliations
Review

Autophagic and apoptotic effects of HDAC inhibitors on cancer cells

Hidemi Rikiishi. J Biomed Biotechnol. 2011.

Abstract

Because epigenetic alterations are believed to be involved in the repression of tumor suppressor genes and the promotion of tumorigenesis in cancers, novel compounds endowed with histone deacetylase (HDAC) inhibitory activity are an attractive therapeutic approach. Indeed, the potential of HDAC inhibitors for cancer therapy has been explored in preclinical models, and some agents approved for hematologic malignancies have reached the clinical setting. HDAC inhibitors are able to mediate the induction of both apoptosis and autophagy, which are related to anticancer activity in a variety of cancer cell lines. Given the inherent resistance to apoptosis that characterizes cancer, the targeting of alternative pathways is an attractive strategy to improve anti-tumor therapy. The activation of autophagy represents novel cancer treatment targets. This paper aims to critically discuss how the anticancer potential of HDAC inhibitors may elicit a response to human cancers through different cell pathways leading to cell death.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Shao Y, Gao Z, Marks PA, Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(52):18030–18035. - PMC - PubMed
    1. Esteller M. Molecular origins of cancer: epigenetics in cancer. New England Journal of Medicine. 2008;358(11):1148–1159. - PubMed
    1. Clayton AL, Hazzalin CA, Mahadevan LC. Enhanced histone acetylation and transcription: a dynamic perspective. Molecular Cell. 2006;23(3):289–296. - PubMed
    1. Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000;403(6765):41–45. - PubMed
    1. Balasubramanian S, Verner E, Buggy JJ. Isoform-specific histone deacetylase inhibitors: the next step? Cancer Letters. 2009;280(2):211–221. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources